Rockwell Medical (NASDAQ:RMTI) Posts Quarterly Earnings Results

Rockwell Medical (NASDAQ:RMTI) announced its quarterly earnings data on Thursday. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05), Zacks reports. Rockwell Medical had a negative return on equity of 16.11% and a negative net margin of 7.67%.The business had revenue of $18.35 million during the quarter, compared to the consensus estimate of $18.58 million.

Here are the key takeaways from Rockwell Medical’s conference call:

• Rockwell reported structural operational improvements with Q4 gross margin rising to 21%, a positive full‑year Adjusted EBITDA, and $2.3M of operating cash flow in Q4, lifting year‑end cash to $25M.
• Net sales declined 32% YoY to $69.3M driven by reduced volumes from a major customer, contributing to a full‑year net loss of $5.3M (including non‑cash charges and restructuring costs).
• Customer diversification strengthened via multi‑year agreements (IRC, Concerto), long‑term supply to DCI, continued supply to Fresenius, a DaVita extension through end‑2026 with higher pricing, and ~30 new West Coast accounts gained after a competitor disruption.
• 2026 guidance targets Adjusted EBITDA of $1M–$2M and positive operating cash flow, with management noting ongoing negotiations with large customers that could further raise revenue and margins.
• Management reiterated a longer‑term ambition to exceed $100M in annual sales by 2029 with margins approaching ~30% and $5M–$10M in annual profit, but emphasized these are directional and subject to execution and market risks.

Rockwell Medical Stock Performance

NASDAQ:RMTI opened at $0.87 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.50 and a current ratio of 3.91. Rockwell Medical has a fifty-two week low of $0.78 and a fifty-two week high of $2.10. The firm has a market cap of $34.29 million, a PE ratio of -5.80 and a beta of 1.71. The business has a 50 day moving average price of $1.01 and a 200-day moving average price of $1.05.

Institutional Investors Weigh In On Rockwell Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd boosted its position in Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after buying an additional 46,029 shares during the period. Jane Street Group LLC purchased a new position in shares of Rockwell Medical in the fourth quarter valued at about $84,000. Vanguard Group Inc. increased its position in shares of Rockwell Medical by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after acquiring an additional 148,737 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Rockwell Medical by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after acquiring an additional 41,668 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors.

Rockwell Medical News Summary

Here are the key news stories impacting Rockwell Medical this week:

• Positive Sentiment: Achieved adjusted EBITDA profitability for the second straight year, showing improved operating leverage that can support the path to sustainable profitability. Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
• Positive Sentiment: Featured in Zacks screens as a value/momentum candidate — this can attract bargain hunters and momentum traders looking for turnaround stories. Should Value Investors Buy Rockwell Medical (RMTI) Stock?
• Neutral Sentiment: Full Q4 earnings call/transcript provides management commentary and color on drivers of the quarter and the FY26 outlook — useful for investors who want to hear management’s execution plan and assumptions. Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed revenue estimates and reported EPS came in below some consensus figures, signaling slower top‑line momentum; several outlets flagged the revenue decline as the main driver of investor concern. Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Management’s cost‑cutting/right‑sizing plan has raised execution risk and could pressure future growth if not managed carefully — analysts flagged this as a demand/execution risk that may weigh on investor confidence. Rockwell Medical’s Cost Cuts Raise Execution Risk and Threaten Future Growth Prospects
• Negative Sentiment: Company issued a FY26 outlook that some market coverage characterized as cautious after the quarter; investors typically punish missed top‑line results and uncertain guidance more than one‑time positives. Rockwell Medical misses top-line estimates; gives FY26 outlook

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on RMTI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $2.50 price objective on shares of Rockwell Medical in a research note on Monday, January 26th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Rockwell Medical presently has a consensus rating of “Hold” and an average price target of $2.50.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.